Inicio
Fármacos Antitumorales
Inhibidores de Akt quinasas

5. Referencias


5.    Referencias

1.
Li Q, Zhu GD. Targeting Serine / Threonine Protein Kinase B / Akt and Cell-cycle Checkpoint Kinases for Treating Cancer. Curr. Top. Med. Chem. 2002, 2, 939.
2.
Graff J R. Expert Opin. Theor. Targets 2002, 6, 103.
3.
Vivanco I, Sawyers C. The phosphatidylinositol 3-Kinase?AKT pathway in human cancer. Nat. Rev. Cancer. 2002, 2, 489-501.
4.
Hanks S, Hunter T. Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification; FASEB J, 1995, 9, 576.
5.
Scheid MP, Woodgett JR. Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett. 2003, 546, 108.
6.
Carpenter CL, Duckworth BC, Auger KR, Cohen B, Schauffhausen BS, Cantley LC, Purification and characterization of phosphoinositide 3-kinase from rat liver. J. Biol. Chem. 1990, 265, 19704.
7.
Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and other D3 phosphoinositide-regulated kinases: Kinase Activation by Phosphoinositide-Dependent Phosphorylation; Annu. Rev. Biochem. 1999. 68, 965.
8.
Sato S, Fujita N, Tsuruo T. Regulation of Kinase Activity of 3-Phosphoinositide-dependent Protein Kinase-1 by Binding to 14-3-3, J. Biol. Chem. 2002, 277, 39360.
9.
Hresko R, Murata H, Mueckler M. Phosphoinositide-dependent Kinase-2 Is a Distinct Protein Kinase Enriched in a Novel Cytoskeletal Fraction Associated with Adipocyte Plasma Membranas. J. Biol. Chem. 2003, 278, 21615.
10.
Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 4240.
11.
Vázquez, E, Sellers W R. Biophys. Acta. 200, 1470, M21.
12.
Woodget JR. Recent advances in the protein kinase B signaling pathway. Curr. Opin. Cell. Biol. 2005, 17, 150.
13.
Del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt., Science 1997, 278, 687. 14 Zha J, Harada H, Yang E, Jockel J, Korsmeyer S. Cell 1996, 87, 619.
15.
Yang E, Zha J, Jockey J, Boise L, Thompson C, Korsmeyer S. Cell 1995, 80, 285.
16.
Crowder R, Freeman R. Glycogen Synthase Kinase-3 Activity Is Critical for Neuronal Death Caused by Inhibiting Phosphatidylinositol 3-Kinase or Akt but Not for Death Caused by Nerve Growth Factor Withdrawal. J. Biol. Chem. 2000, 275, 34266.
17.
Pap M, Cooper G. Role of Glycogen Synthase Kinase-3 in the Phosphatidylinositol 3-Kinase/Akt Cell Survival Pathway. J. Biol. Chem. 1998, 273, 19929.
18.
Staal SP. Molecular Cloning of the akt Oncogene and Its Human Homologues AKT1 and AKT2: Amplification of AKT1 in a Primary Human Gastric Adenocarcinoma. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 5034
19.
Coppola D, Cheng JQ, Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 2000, 19, 2324.
20.
Sourbie C, Lindner V, Lang H, Agouni A, Schordan E, Danilin S, Rothhut S, Jacmin D, Helwing J, Massfelder T. The Phosphoinositide 3-Kinase/Akt Pathway: A New Target in Human Renal Cell Carcinoma Therapy. Carcer Res. 2006, 66, 5130.
21.
Li Q, Zhu GD, Gong J, Jonson E, Giranda V. et al. Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation. Bioor. & Med. Chem. Lett. 2006, 16, 1679.
22.
Li Q, Zhu GD, Gong J, Jonson E, Giranda V. et al. Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: Discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer. Bioor. & Med. Chem. Lett. 2006, 2000-2007.
23.
Li Q, Zhu GD, Gong J, Jonson E, Giranda V. et al. Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity. Bioor. & Med. Chem. Lett. 2006, 3150-3155.
24.
Li Q, Zhu GD, Gong J, Jonson E, Giranda V. et al. Discovery and SAR of oxindole-pyridine-based protein kinase B/Akt inhibitors for treating cancers. Bioor. & Med. Chem. Lett. 2006, 3424-3429.
25.
Fisher J, Thomas S, Luo Y, Giranda V, Li Q. Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors. Bioorg. & Med. Chem. 2006, 14, 6832.
26.
Luo Y, Oltersdorf T, Rosenberg S, Li Q, Giranda V. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther 2005;4(6).
27.
Barnett S, Defeo-Jones D, Hancock P. et al. Identification and characterization of Pleckstrin-homology-domain dependent-specific Akt inhibitors. Biochem. J. 2005, 399-408.
28.
Nakatani K, Thomson DA, Barthel A, Sakaue H, Liu W, Weigel RJ, Roth RA. J. Biol, Chem. 1999, 274, 10767-10774.
29.
Lidsley CW, Zhao Z, Leister W, Duggan M. et al. Allosteric Akt inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg. & Med. Chem. Letters 15, 2005, 761-764.
30.
Zhao Z, Leister W, Barnett S, Lindsley CW. Discovery of 2,3,5-trisubstitued pyridine derivatives as potent Akt1 and Akt2 dual inhibitors. Bioorg. & Med. Chem. Letters 15, 2005, 905-909.
31.
Hu Y, Qiao L, Kozikowski A, et al. 3-(hydroxymethyl)-Bearing Phosphatidylinositol Ether Lipid Analogues and Carbonate Surrogates block PI3K, Akt and Cancer Cell Growth. J. Med. Chem. 2000, 43, 3045-3051.
32.
Kozikowski A, Sun H, Brognard J, Dennos P. A. Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. J. Am. Chem. Soc. 2003, 125, 1144.
33.
Rong S, Hu, Y.; Kozikowski, A. et. Al. Molecular modeling studies of the Akt PH domain an dits interaction with phosfoinositides. J. Med. Chem. 2001, 44, 898-908.
34.
Ringel MD et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res. 61, 6105-6111 (2001).
35.
Sun M, et al. AKT1/PKBa kinase is frequently elevated in human cancers and its constitutive activation is required foroncogenic transformation in NIH3T3 cells. Am. J. Pathol.159, 431-437 (2001).
36.
Vivanco I, Sawyers C. The phosphatidylinositol 3-Kinase?AKT pathway in human cancer. Nat. Rev. Cancer. 2002, 2, 489.
37.
Breitenleichner C, Wegge T, Berillon L, Graul K, Marzenell K, Friebe W, , Masjost TB. Structure based optimization of novel azepane derivatives as PKB inhibitors. J. Med. Chem. 2004, 47, 1375-1390.
38.
Breitenlechner C, Friebe W-G, Brunet E, Masjost B, et al. Design and crystal structures of protin kinase B-selective inhibitors in complex with protein kinase A and mutants. J. Med. Chem. 2005, 48, 163-170.
39.
Jin X, Gossett D, Cao Y, Guo R, Reynolds R, Lin J, Wang S, Yang D. Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells. British Journal of Cancer, 2004, 91, 1808
40.
Mauffret O, Rene B, Convert O, Monnot M, Lescot E, Fernandjian S, Biopolymers 1991, 31, 1325.
41.
Schwaller MA, Dodin G, Aubard J. Thermodynamics of drug-DNA interactions: Entropy-driven intercalation and enthalpy-driven outside binding in the ellipticine series, Biopolymers 1991, 31, 519.
42.
Adenier A, Aubard J, Schwaller MA. Thermodynamics and kinetics of aggregation processes in aqueous media of ellipticine derivatives: the alkyl-oxazolopyridocarbazole series. J. Phys. Chem. 1992, 96, 8785.
43.
Aubard J, Schwaller JP, Marsault GL. Surface-enhanced Raman spectroscopy of ellipticine, 2-N-methylellipticinium and their complexes with DNA. J. Rhaman Spectrosc. 1992, 23, 373.
44.
Stambolic V, Suzuki A, de la Pompa J, Brothers G, Mirtsos C, Sasaki, T, Ruland J, Penninger J, Siderovski D, Mak T. Cell 1998, 95, 29.
45.
Kanamori Y, Kigawa J, Itamochi H, Shimada M, Takahashi M, Sato S, Akeshima R, Terakawa N. Clin Cancer Res. 2001, 7, 892
46.
Jin X, Cao Y, Chen J, Gossett D, Lin J, Wang S, Yang D. Gynecologic Oncology, 2006, 100, 308.
47.
Kuntebommanahalli NT, Easton J, Germain G, Morton C, Kamath S, Buolamwini J, Houghton P. J. Biol. Chem. 2005, 280, 31294. 48.      Ko JH, Yeon SW, Ryu JS, Kim TY, Song E, You HJ, Parka RE, Ryua CK. Bioorg. & Med. Chem. Lett. 16, 2006, 6001-6005.